Sep 6, 2016Target Company is a biotech company that has developed a sub-micron delivery technology for both small and large molecules. The company has already applied its delivery system to nutraceutical products and produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. It's a R&D organization. They utilize state-of-the-art nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain healthy lives. Their research and development scientists have more than 60 years of combined experience and are dedicated to providing the best nutraceutical products for natural comfort, health, and their well-being.

Diabetes is a chronic disease that affects not only the health of people living with diabetes, but also imposes significant direct and indirect costs on them and on society as a whole. These costs have escalated sharply over the last decade and are expected to continue their rapid ascent for the foreseeable future. It is a personal crisis for people living with the disease, and for their family. It is also a financial crisis for their healthcare system. It is consuming an ever-larger share of provincial and territorial healthcare budgets, and will force an increase in those expenditures.

Company is concentrating on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. The Company is in the early stages of research with respect to all of its technologies.

The intraoral insulin tablet is targeted towards patients with Type 2 diabetes as well as patients with pre-diabetes. These populations represent the largest segment of the global diabetic population (387 million people) with expected worldwide rising disease prevalence to 592 million by 2035. An analysis of these conditions has shed light on pre-diabetes, encouraging early detection and early treatment of the disease. It is predicted that early administration of insulin to pre-diabetics and type 2 diabetic patients would not only help to control blood glucose but also may significantly decelerate disease progression. Fear of needles and lack of a convenient non-invasive dosage form for insulin delivery may be the main reasons against wide use and early start of insulin administration.

Company is looking to raise $10mn in Convertible Preferred Shares.

Company is listed on Nasdaq Pink Sheets. Management has around 80% of the shares.

Conservative projections of taking only 0.25% of target market share (Malaysia, Mexico and Canada) will result with more than 100% ROI for the investor as at Dec 2019.

Financial Projections:
Year Revenue EBITA
2015 134,000 -4m
2016 3.4m -3m
2017 21m 2.5m
2018 83m 38m
2019 172m 88.4m

Sign up today to learn more about this deal and others like it.

By clicking "Sign Up Now - It's Free" you confirm that you accept the Terms of Use and Privacy Policy, including cookie use.